BACKGROUND OF THE INVENTION
The field of the present invention relates to the delivery of energy impulses (and/or fields) to bodily tissues for prophylactic purposes. It relates more specifically to the use of non-invasive devices and methods for transcutaneous electrical nerve stimulation and
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the substituted quinoxaline 2-ones type. The compounds are active as excitatory amino acid receptor antagonists acting at glutamate receptors, including either or both
BACKGROUND OF THE INVENTION
The present invention concerns novel sulfonamide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by sulfonamide derivatives. The
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a or b position by amino acid derivatives. The compounds are active as excitatory amino
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase of International Application No. PCT/US2014/027450 filed on Mar. 14, 2014, which claims the benefit of U.S. Provisional Application No. 61/785,478 filed on Mar. 14, 2013, each of which are incorporated herein by reference
This application is a U.S. national stage of International Application No. PCT/JP03/03115 filed Mar. 14, 2003.
TECHNICAL FIELD
The present invention is useful in medical fields. In more detail, novel pyridone derivatives of the present invention have an effect as neuropeptide Y receptor antagonists
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Phase application under 35 U.S.C. .sctn.371 of PCT Application No. PCT/JP2005/004379, filed Mar. 7, 2005, which claims priority under 35 U.S.C. .sctn.119 from JP Application No. JP2004-062343, filed Mar. 5, 2004.
TECHNICAL
FIELD OF THE INVENTION
The present invention generally relates to methods for treating, controlling or preventing medical, psychiatric or neurological disorders by application of modulating electrical signals to a selected nerve or nerve bundle of a patient, and more particularly to techniques for
BACKGROUND TO THE INVENTION
The present invention is generally in the field of therapeutic formulations for delivering gamma-hydroxybutyrate.
Gamma-hydroxybutyrate ("GHB") is a naturally occurring substance that is widely distributed in the mammalian body, being present, for example, in the brain,
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Phase application under 35 U.S.C. .sctn.371 of PCT Application No. PCT/JP2005/012442, filed Jun. 29, 2005, which claims priority under 35 U.S.C. .sctn.119 from JP Application No. JP2004-194410, filed Jun. 30, 2004.
TECHNICAL
BACKGROUND OF THE INVENTION
The field of the present invention relates to the delivery of energy impulses (and/or fields) to bodily tissues for prophylactic purposes. It relates more specifically to the use of non-invasive devices and methods for transcutaneous electrical nerve stimulation and
CROSS REFERENCE TO RELATED APPLICATIONS
This is a National Stage of International Application No. PCT/JP2009/067441 filed Sep. 30, 2009, claiming priority based on Japanese Patent Application No. 2008-257072 filed Oct. 2, 2008, the contents of all of which are incorporated herein by reference in
FIELD OF THE INVENTION
The present invention concerns novel urea and thiourea derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by urea or thiourea derivatives. The
TECHNICAL FIELD
The present invention relates to drugs, particularly to novel isoquinoline derivatives or salts having a I.sub.f current inhibitory effect without serious side effects such as convulsion and also to drugs, particularly cardiac rate lowering agents containing these compounds as the
BACKGROUND OF THE INVENTION
The present invention concerns novel amide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by amide derivatives. The compounds are active
Najkompletnija baza ljekovitog bilja potpomognuta naukom
Radi na 55 jezika
Biljni lijekovi potpomognuti naukom
Prepoznavanje biljaka po slici
Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
Pročitajte naučne publikacije povezane sa vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi. * Sve informacije temelje se na objavljenim naučnim istraživanjima